IgA Nephropathy Pipeline Insight 2025

IgA nephropathy (IgAN) is the most common primary glomerular disease that can progress to end-stage renal failure (ESRD), with a subset of patients experiencing rapid disease progression and renal failure within years if not treated. Recent advancements in the IgA Nephropathy pipeline have led to the development of innovative therapies, with 25+ companies and 30+ pipeline drugs in the IgA Nephropathy pipeline landscape.

Key Takeaways:

On 14 October 2025, Alpine Immune Sciences Inc. announced a clinical study to evaluate multiple dose levels of povetacicept in adults with immunoglobulin A (IgA) nephropathy (IgAN).
On 08 October 2025, Novartis Pharmaceuticals conducted a study to demonstrate the superiority of iptacopan (LNP023) at a dose of 200 mg b.i.d. compared to placebo on top of maximally tolerated ACEi or ARB on reduction of proteinuria and slowing renal disease progression in primary IgA Nephropathy patients.
DelveInsight's IgA Nephropathy Pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for IgA Nephropathy treatment.
Leading IgA Nephropathy Companies include Chinook Therapeutics, Guangdong Hengrui Pharmaceutical Co., Ltd., Takeda, Visterra, Novartis Pharmaceuticals, Wuhan Createrna Science and Technology, Jiangsu HengRui Medicine Co., Ltd., Takeda, Selecta Biosciences, Shanghai Alebund Pharmaceuticals, and others.
Promising IgA Nephropathy Therapies include LNP023, Blisibimod, HR19042 Capsules, Telitacicept, Intravenous Rituximab, Nefecon, BION-1301, Atrasentan, and others.
IgA Nephropathy Pipeline report highlights the unmet needs with respect to the disease.
IgA Nephropathy emerging drugs, such as Atrasentan, SHR-2010, and TAK-079, have shown potential in treating the disease.
The pipeline report provides insights into the therapeutic assessment of pipeline drugs by route of administration and molecule type.

Statistics:

25+ active players working on 30+ pipeline therapies for IgA Nephropathy treatment.
14 October 2025: Alpine Immune Sciences Inc. announced a clinical study to evaluate povetacicept in IgAN patients.
08 October 2025: Novartis Pharmaceuticals conducted a study to demonstrate the superiority of iptacopan (LNP023) in primary IgA Nephropathy patients.
30+ pipeline therapies in the IgA Nephropathy pipeline landscape.
5+ leading IgA Nephropathy companies working on innovative therapies.

Sources:

M2 PRESSWIRE - October 20, 2025 - IgA Nephropathy Pipeline Drugs Report 2025: Latest Drugs, Emerging Therapies, and Clinical Trials Shaping
DelveInsight's IgA Nephropathy Pipeline Insight 2025 report
Alpine Immune Sciences Inc. clinical study announcement (14 October 2025)
Novartis Pharmaceuticals study announcement (08 October 2025)
DelveInsight's IgA Nephropathy Pipeline report